Inventor · disambiguated record
Pascal Deschatelets
Also filed as: DESCHATELETS PASCAL
32 granted patents·40 pending applications·370 citations·filing 2001–2025
97Inventor score
Files withAPELLIS PHARMACEUTICALS INC41FRANCOIS CEDRIC11POTENTIA PHARMACEUTICALS INC6DESCHATELETS PASCAL3KING S COLLEGE LONDON3
Top patents by PatentIndex Score
72 records- 0197US9421240B2Compstatin analogs for treatment of neuropathic painFRANCOIS CEDRIC·Filed 2011·Granted Aug 23, 2016·41 cites·9 claims
- 0296US8580735B2Local complement inhibition for treatment of complement-mediated disordersFRANCOIS CEDRIC·Filed 2008·Granted Nov 12, 2013·50 cites·21 claims
- 0395US9056076B2Method of treating age-related macular degeneration comprising administering a compstatin analogDESCHATELETS PASCAL·Filed 2012·Granted Jun 16, 2015·39 cites·19 claims
- 0495US8168584B2Methods of treating age-related macular degeneration by compstatin and analogs thereofDESCHATELETS PASCAL·Filed 2006·Granted May 1, 2012·44 cites·58 claims
- 0594US10407466B2Methods of selecting compstatin mimeticsAPELLIS PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·12 cites·2 claims
- 0693US11292815B2Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2020·Granted Apr 5, 2022·2 cites·11 claims
- 0793US11001610B2Cell-reactive, long-acting, or targeted compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2018·Granted May 11, 2021·4 cites·23 claims
- 0893US10875893B2Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2018·Granted Dec 29, 2020·10 cites·9 claims
- 0993US10308687B2Cell-penetrating compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2014·Granted Jun 4, 2019·14 cites·13 claims
- 1093US10035822B2Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2013·Granted Jul 31, 2018·15 cites·12 claims
- 1192US12290566B2Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2023·Granted May 6, 2025·2 cites·20 claims
- 1292US11844841B2Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2021·Granted Dec 19, 2023·4 cites·26 claims
- 1392US11407789B2Cell-penetrating compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2020·Granted Aug 9, 2022·2 cites·11 claims
- 1492US10125171B2Cell-reactive, long-acting, or targeted compstatin analogs and uses thereofFRANCOIS CEDRIC·Filed 2012·Granted Nov 13, 2018·16 cites·21 claims
- 1592US8043609B2Viral complement control proteins for eye disordersPOTENTIA PHARMACEUTICALS INC·Filed 2006·Granted Oct 25, 2011·14 cites·14 claims
- 1690US7947267B2Viral complement control proteins for eye disordersPOTENTIA PHARMACEUTICALS INC·Filed 2005·Granted May 24, 2011·19 cites·59 claims
- 1789US9291622B2Complement assays and uses thereofZHANG ZHOUNING·Filed 2010·Granted Mar 22, 2016·24 cites·20 claims
- 1888US11040107B2Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2018·Granted Jun 22, 2021·9 cites·24 claims
- 1988US10941184B2Cell-penetrating compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2019·Granted Mar 9, 2021·3 cites·11 claims
- 2088US2025282823A1Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2186US11013782B2Methods of treating chronic disorders with complement inhibitorsAPELLIS PHARMACEUTICALS INC·Filed 2019·Granted May 25, 2021·1 cites·24 claims
- 2283US10039802B2Methods of treating chronic disorders with complement inhibitorsFRANCOIS CEDRIC·Filed 2012·Granted Aug 7, 2018·5 cites·23 claims
- 2383US2024076317A1Cell-reactive, long-acting, or targeted compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2482US11903994B2Dosing regimensAPELLIS PHARMACEUTICALS INC·Filed 2016·Granted Feb 20, 2024·4 cites·10 claims
- 2581US11101026B2Schedule-based electronic medical record modules, applications, and uses thereofREVON SYSTEMS LLC·Filed 2015·Granted Aug 24, 2021·6 cites·20 claims
- 2680US8198020B2Compositions and methods for enhancing phagocytosis or phagocyte activityFRANCOIS CEDRIC·Filed 2004·Granted Jun 12, 2012·17 cites·59 claims
- 2778US2023091471A1Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2876US11661441B2Cell-reactive, long-acting, or targeted compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2021·Granted May 30, 2023·0 cites·34 claims
- 2976US2023075121A1Cell-penetrating compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3075US11712460B2Methods of treating chronic disorders with complement inhibitorsAPELLIS PHARMACEUTICALS INC·Filed 2021·Granted Aug 1, 2023·0 cites·19 claims
- 3174US2024285783A1Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3273US12458695B2Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2025·Granted Nov 4, 2025·0 cites·30 claims
- 3373US10696718B2Compstatin analogs for treatment of neuropathic painAPELLIS PHARMACEUTICALS INC·Filed 2018·Granted Jun 30, 2020·0 cites·3 claims
- 3471US7329461B2Flame-retardant synthetic resin articles containing flame-retardant superabsorbent polymer (SAP) particlesLUNA INNOVATIONS INC·Filed 2005·Granted Feb 12, 2008·1 cites·28 claims
- 3571US2020325175A1Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3670US2022088131A1Compositions and methods relating to c5l2KING S COLLEGE LONDON·Filed 2021·Application pending·0 cites
- 3770US2021107944A1Compstatin analogs for treatment of neuropathic painAPELLIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3867US11291407B2Detection of high risk drusenAPELLIS PHARMACEUTICALS INC·Filed 2020·Granted Apr 5, 2022·0 cites·7 claims
- 3967US7001942B2Flame retardant thermoset resins and methods of making the sameLUNA INNOVATIONS INC·Filed 2004·Granted Feb 21, 2006·5 cites·14 claims
- 4066US2016194359A1Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4165US2017166610A1Compstatin Analogs for Treatment of Neuropathic PainAPELLIS PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4264US2020316163A1Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4363US2019201488A1Compositions and methods relating to c5l2KING S COLLEGE LONDON·Filed 2018·Application pending·0 cites
- 4462US2017283461A1Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 4562US2015150945A1Modifying Macrophage Phenotype for Treatment of DiseaseAPELLIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4662US2016271216A1Compositions and methods relating to c5l2KING S COLLEGE LONDON·Filed 2014·Application pending·0 cites
- 4761US7198747B2Fabrication of ceramic microstructuresHARVARD COLLEGE·Filed 2001·Granted Apr 3, 2007·7 cites·62 claims
- 4861US2024110182A1Genomic editing of complementAPELLIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4960US2009220572A1Injectable Combination Therapy for Eye DisordersPOTENTIA PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 5060US2019192617A1Methods of treating chronic disorders with complement inhibitorsAPELLIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
Showing the top 50 of 72 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Pascal Deschatelets files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →